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ABSTRACT 
Persistent development in nanomedicine has enabled successful nano-sizing of 
most drug samples, which in turn imparts remarkable properties to the drugs such as 
enhanced solubility and bioavailability for the applications in drug delivery.  In this 
context, several review articles are available in scientific domain covering inorganic 
nanoparticles such as Au, Ag, SPIONs, Qdots, carbon nanotubes and graphene 
however this review covers the development of drug nanoparticles together with their 
possibilities and limitation from fabrication (bottom up vs top down) to application in 
drug delivery during the last 5 years.  In addition, some distinguished studies and 
novel drug particles are presented in order to contribute significantly towards the 
understanding of drug nanocrystals and its use in drug delivery. 
Keywords: Nano-suspension, Amorphous / Crystalline nanoparticles, Top down / 
Bottom up, Drug-nanocrystals, Nano-carriers, Drug Delivery  
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Introduction 
Modern material science is no longer restricted to the metallurgical application, as 
the advancement in the nanotechnology is opening unlocked doors in various fields. 
For over a decade, extensive research is being undertaken using nanoparticles for 
its application in medicines, environmental projects, electrical and electronics, 
aerospace and lifestyle industries. These nanoparticles of nanometer in size ranging 
from 1 to 1000 nm possess great advantages as compared to the microsized 
particles.  
Development of a large number of drugs and their delivery without any side effects to 
the patients are the real challenges faced by scientific community.  Most of the drug 
molecules are large organic molecules and have poor solubility in water.  Hence a 
huge effort has been made for nanosizing the drug particles in either an amorphous 
or crystalline nanosuspension for applications in passive targeting due to enhanced 
membrane diffusion. Similarly an effort has been made for the development of 
several carriers for delivering drugs and functionalisation of carriers to enhance the 
active delivery at a target organ. Furthermore, the nanosize of drug particles imparts 
remarkable properties to the drugs such as enhanced solubility and bioavailability. 
Therefore this review is focussed on critically highlighting the nanomedical use of 
various drug nanocrystals, especially for drug delivery applications.  
Recent trends 
Nanoparticles’ use has increased exponentially for the drug formulations and drug 
delivery in the last decade. Increased efforts are applied to monitor the structure – 
function relationship of the nanoparticles for targeted drug delivery applications. 
There has been some novel nanodrugs produced recently such as the Copazone, 
Welchol, VivaGel and RenaGel. Copazone is a random co-polymer of the four main 
amino acids which is employed to treat muscular sclerosis [1]. Welchol is a drug 
which helps to lower the low density lipoprotein (LDL) cholesterol and blood sugar 
level by binding the cholesterol [2]. VivaGel is a topically administered vaginal 
virucide which is a multivalent lysine based dendrimer product [3]. RenaGel is an oral 
polymeric sequestrant that binds to phosphate and is used to treat chronic kidney 
disease [4]. In addition, a timeline is reviewed in Figure 1 to show the FDA approved 
amorphous and crystalline drugs since 1984 [5].  
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Figure 1: Timeline reviewing FDA approved crystalline & amorphous drugs 
(Reproduced with permission from ref [5]) 
Most of the current cancer therapies and drug formulations are based on the 
nanoparticle approach to improve the bioavailability and solubility of the 
encapsulated drugs at the target site. There is an increased use of nanosuspensions 
for drug delivery application, especially for topically administered drugs since 
nanosuspensions increases the bioavailability of drugs due to increased permeation. 
For instance, as shown in Figure 2, nanosuspensions exhibit higher permeability and 
high concentration gradient for both topical and subcutaneously administered drugs 
compared to microparticles [6].  A multi-disciplinary principle is employed nowadays 
to tailor the nanoparticles in order to incorporate specific properties, such as DNA 
functionalisation using molecular biology and genetics, ion conductivity using the 
semiconductor physics, solubility and stability using the organic chemistry, and so 
on. For example, β-Lapachone or simply β-Lap is a novel anticancer drug 
demonstrated to be delivered by 30 nm PEG-PLA polymer micelles to the lungs of 
mice. The drug was injected intravenously and was bioactivated by the enzyme 
NAD(P)H:quinon oxidoreductase-1 (NQO1) that is found in excess levels at the non-
small-cell lung cancer sites [7].  
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Figure 2: Scheme showing enhanced permeability of drug nanosuspension 
Drug particles in Nanosuspension 
In simple terms, a submicron colloidal dispersion of the nanoparticles (in either 
amorphous or crystalline form) is called as a nanosuspension. A drug specific 
nanosuspension consists of dispersed, finely colloidal and mostly biphasic drug 
particles with an overall size of less than 500 nm [8]. These drug-nanoparticles 
conjugates can be stabilised using polymers and surfactants before administration 
through various routes such as topical, oral, pulmonary, ocular or parenteral [6]. 
Different ingredients are used for formulation of nanosuspensions such as organic 
solvents, cosurfactants, stabilisers and other additives such as salts, polyols, buffers, 
cryoprotectants and osmogents [9].   
Solubility and bioavailability of drugs are the key issues that are mitigated using the 
nanosuspensions. In addition, the nanosuspension also affects the drug’s 
pharmacokinetics that can improve its efficacy and safety. Both chemical and 
physical modifications are applied to improve the solubility and bioavailability of 
drugs [10]. Chemical modifications include synthesising the soluble salts and 
prodrugs, whereas the physical modifications include reducing particle size, use of 
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surfactants for solublisation/complexation, forming pseudo-polymorphs/polymorphs 
and preparing drug dispersions [11-15]. Different types of composite structure results 
from nanoparticles in suspension, as shown in Figure 3.  Various factors and 
techniques are responsible to form composite structures such as the core shell, 
internal dispersion, agglomeration, coating/surface modification, hollow, porous, 
nano-dense body, nano-porous body and nano-thin film [16].   
 
Figure 3: Types of composite structures formed from nanoparticles in suspension 
Functionalisation of nanocrystals 
A schematic review of the various ligands surface functionalised on a nanocrystals 
core is shown in Figure 4 [17]. It can be seen that a drug nanocrystal core can be 
surface modified for specific applications by tailoring the type of ligands attached to it 
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with the help of a polymer coating. For instance, magnetic ligands can be used for 
magnetically targeting to tumor sites followed by hyperthermia applications, where 
the drug could be released systematically due to localised hearing. The use of image 
contrast ligand facilitates the diagnostic monitoring of drug release and provide real 
time data about the pharmacokinetics of the drug. Furthermore, the surface of 
nanocrystal core could be functionalised with uptake, targeting or adhesion ligands 
to provide an active transport or targeting to tumor sites in in vivo. For instance, 
nanocrystal implants are exploiting these surface functionalised drug nanocrystals as 
therapeutic vehicles to identify, transfect and rebuild damaged regions in the body 
[18].  
 
Figure 4: Surface functionalization of nanocrystals (Reproduced with permission 
from ref [17]) 
Methods of preparation of nanosuspension 
Nanosuspensions can be prepared using both bottom-up and top-down approaches. 
These methodologies are widely applied in nanomedicine due to its consistency to 
produce nanoparticles of controlled aspect ratio [19]. The bottom-up methods are 
called as conventional precipitation methods whereas the top-down methods are 
referred to as disintegration methods. The top-down methods are further classified 
as media milling and high pressure homogenisation (HPH) methods, where the latter 
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is sub-classed into DissoCubes (HPH in water), Nanopure (HPH in nonaqueous 
media) and Nanoedge (HPH and precipitation) [20].   Figure 5 present a schematic 
diagram of two different approaches for the fabrication of drug nanoparticles. 
 
Figure 5: Various methods of nanosuspension preparation 
Top down method of nanosuspension preparation aims to reduce particle size into 
nanoparticles using wet milling techniques such as high pressure homogenisation, 
microfluidisation and media milling. There are no harmful solvents used in these 
techniques but media milling method requires high energy inputs [21]. In general, 
considerable amounts of heat is generated in the top down methods leading to 
destruction of heat sensitive drug components. For example, milling is reported to 
cause mechanical activation at surfaces of drug particles [22]. High surface energetics 
lead to generation of amorphous regions and crystal defects. Further crystallisation 
of the drug particles reduces the physical and chemical stability of particles on 
storage [23].  
Nanosuspensions
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Bottom up method of nanosuspension preparation aims to produce nanoparticles 
from precipitate by first dissolving the drug in an organic solvent followed by adding a 
precipitating agent in the presence of a stabiliser [24]. Some forms of this method 
include supercritical fluid processes, solvent anti-solvent method, emulsion solvent 
evaporation and spray drying.  Some of the limitations of bottom up method include 
generation of unstable polymorphs, solvates and hydrates of the nanosuspension 
constituents [25, 26]. Furthermore, the difficulty of completing removing the solvents 
from the final product is persistent in bottom up method. This reduces the physical 
and chemical stability of the formulation, as it is often seen that bottom up method 
results in needle shaped particles due to rapid unidirectional growth [24].  
A study of some of the recent nanosuspensions prepared through various routes for 
drug delivery is shown in table 1 [27 - 42]. The table highlights both amorphous and 
crystalline nanosuspensions along with the particle size, method of preparation and 
main conclusions from the studies.  
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Table 1: A study of the recent (5 years) drug nanoparticles in both crystalline and amorphous forms [27 – 42] 
Type of 
nanoparticle 
Particle 
size 
(nm) 
Drug/Polymer used 
Method of 
preparation 
Focus of article Conclusion Ref. 
Amorphous 
nanoparticle 
suspension 
350 Cylosporin A (CyA) Bead milling 
Enhance applications in 
psoriasis or dermal 
penetration 
Higher penetration using 
amorphous CyA 
nanoparticles 
27 
Amorphous 
nanosuspension 
50-500 Isradipine Sonoprecipitation 
Enhance drug delivery for 
increased dissolution rates 
Improved drug release rate 
was observed 
28 
Nanosuspension 
(crystalline to 
amorphous) 
300 -500 Myricetin 
Nanosizing 
process 
Effect of stabilizers on 
bioavailability/ dissolution of 
poorly water-soluble drugs 
Stabilizers enhanced 
dissolution, amorphisation 
enhanced solubility 
29 
Nanosuspension 
(crystalline to 
amorphous) 
208 -246 
Cur-TPGS NSs 
(Curcumin-D-α-
Tocopherol PEG 
1000 succinate) 
Sonoprecipitation, 
ultrasonic 
homogenization 
To enhance the solubility of 
formed nanosuspension 
Cur-TPGS NSs showed 
higher solubility & oral 
adsorption 
30 
Nanosuspension 
(crystalline) 
< 150 
Anticancer 
compound, 
SN 30191 
Wet milling 
Evaluation of crystalline 
nanosuspension as a cancer 
drug 
Crystalline nanosuspension 
showed high tolerance & 
drug delivery 
31 
Nanocrystals to 
Amorphous 
nanosuspension 
150-175 Curcumin 
Antisolvent 
precipitation 
method 
Enhance bioavailability of 
curcumin by nanosizing and 
amorphisation 
Nanosized & amorphous 
nanosuspension shows the 
maximum stability 
32 
Crystalline 
nanosuspension 
200-350 
BCS class II/IV 
compounds 
Spray drying 
Enhance dissolution using 
nanocrystalline suspensions 
Faster dissolution was 
obtained subject to drug-to-
excipient ratio 
33 
Amorphous & NA Nanosuspensions Freeze drying Effect of critical formulation Freeze drying does not 34 
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crystalline 
nanosuspension 
with steric stabilizers temperature (CFT) and 
freeze drying on drug’s 
stability 
affect drug’s stability 
Amorphous & 
crystalline 
nanosuspension 
300 Hydrocortisone (HC) 
Microfluidic 
nanoprecipitation 
(bottom-up) & wet 
milling (top-down) 
Bottom up and top down 
methods for ophthalmic drug 
Top-down showed high 
stability as compared to the 
bottom-down 
35 
Crystalline 
nanosuspension 
88, 122, 
362 
Compounds 
(celecoxib, griseo-
fulvin, fenofibrate, 
and compound-X) 
Ultracentrifugation 
& filtration 
Dissolution rate dependence 
on  the Noyes-Whitney 
equation 
Low dependence 
36 
 
 
Amorphous and 
crystalline 
nanosuspensions 
274 Ziprasidone 
Lyophilisation and 
milling 
Improving drug absorption in 
the fasted state (in-vitro 
studies) 
Amorphous 
nanosuspension showed 
high absorption 
37 
Crystalline & 
amorphous 
nanosuspension 
323-734 Itraconazole (ITZ) 
HME and wet 
milling 
Effect of methods on 
Itraconazole (ITZ) for both in 
vitro & in vivo 
HME method showed 
higher dissolution & 
bioavailability 
38 
Crystalline & 
amorphous 
nanosuspension 
300 
Drug/polymeric 
complex 
Wet-milling 
Increase solubility & 
dissolution rate by nanosizing 
Higher solubility & 
dissolution rate upon 
nanosizing 
39 
Amorphous 
nanosuspension 
>600 
Ezetimibe 
nanosuspension 
Precipitation 
Enhance oral bioavailability  
of ezetimibe 
Amorphous precipitation 
increases oral bioavailability 
40 
Crystalline 
nanosuspension 
699 Fenofibrate 
Bead-milling 
method 
Spray drying 
Effect of methods on 
bioavailability & dissolution 
The dissolution was found 
faster in the spray dried 
powder 
41 
Crystalline 
nanosuspension 
397 Indomethacin Spray drying 
Effect of spray drying on 
powder yields 
High yields with lower 
moisture content 
42 
Page 11 of 29
https://mc04.manuscriptcentral.com/fm-nnm
Nanomedicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
12 
 
Size measurement of nanoparticles in suspension 
The size and number of atoms within a single nanoparticle controls the 
morphological aspects of these particles, in addition to other chemical and physical 
properties. For instance, the smallest hydrogen atom has a diameter of about 0.074 
nm whereas a lead atom is about 0.32 nm. Therefore in a single nanoparticle, there 
can be ten to hundreds of atoms present based on the bonding types and 
composition [16]. One of the most important properties attained on transforming 
micro-sized particles into nanoparticles is the massive increase in the surface area. 
This increased surface area imparts enhanced solubility and reaction rates for the 
particles, which is a key desire in modern science. Other properties such as 
dielectric constant, melting point and even crystal lattice are affected due to the “size 
effect”.  
The size measurement for nanoparticles can be done using a range of 
characterisation techniques such as imaging using electron microscope from SEM 
and TEM, peak widths at half maximum from X-ray diffraction, surface area analysis 
from BET and Brownian motion calculation using Dynamic Light Scattering in 
Zetasizer instrument. The imaging techniques are considered to be relatively easy 
and quick as compared to others since it can provide visual inspection of the 
particles as well. However, the sample preparation is a critical step that determines 
the quality of image an accuracy of size measurements.  
The X-ray method is on the other hand considered complex but relatively precise in 
estimating the average particle size from peak properties. But on a nanoscale, it is 
also subjected to limitations of sample preparation and orientation to the electron 
beam. Surface area analysis from BET is relatively simpler to estimate particle size 
but the assumption of spherical shape for calculation is not applicable to all types of 
nanoparticles. Furthermore, the inner structure and surface state of particles can 
affect the calculations and thereby the size of nanoparticles. The application of 
Zetasizer is widely recognised in literatures for determining the size of particles in 
nanosuspensions [16, 43 - 45]. 
A summary of the most common analytical techniques for characterisation of 
nanoparticles is shown in the Figure 6. These techniques are helpful in studying 
various aspects of the nanoparticles such as X-ray diffraction for amorphous or 
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crystallinity study, SEM/EDX and AFM for surface morphology study, TEM for 
internal structure study, AGM, VSM and SQUID for magnetic property study and so 
on.  
 
Figure 6: Useful analytical techniques to study various properties of nanoparticles 
Amorphous vs Crystalline Nanoparticles in Nanomedicine 
It is possible to synthesise various drug nanoparticles used in nanomedicine as 
either amorphous or crystalline forms. On one hand, there is a well-defined crystal 
structure with some crystal defects located on the surface and bulk of the crystalline 
nanoparticles. On the other hand, structural disorderedness is evident throughout the 
nanoparticles in amorphous state providing a more porous framework with high 
structural defects [46 - 48]. These structural differences arise due to different methods 
of nanoparticles preparation. Both bottom up and top down approaches can produce 
particles with varying crystallinity and other physio-chemical properties. 
Most of the drug nanoparticles are prepared using top down approaches, among 
which high pressure homogenisation (HPH) is widely used. HPH process consists of 
3 main steps [49 - 54]: 
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• Dispersion of powdered drug in a solution of water and stabiliser 
• Comminution of coarse particles of drug under low pressure homogenisation 
to prevent blockage of homogenisation chamber 
• High pressure homogenisation using repetitive cycles to attain the desired 
particle size and distribution 
The number of cycles and pressure of homogenisation are the critical factors which 
control the particle size and distribution. For example, the polydispersity index and 
particle size of amoitone B nanocrystals is reported to gradually reduce with an 
increase in number of cycles and homogenisation pressure in a stepwise manner [52]. 
However, once the particles become highly uniform non-aggregated then a 
continuous increase in the pressure or number of cycles has little effect on particle 
size and polydispersity index [52]. 
HPH is also often combined with precipitation process to prepare nanocrystals. In 
this process, first the precipitation of drug is done in a liquid medium that produces 
comminuted drug crystals. Then high pressure homogenisation using repetitive 
cycles is applied to achieve the desired particle size [55, 56]. The main requirement of 
this process is that the drug should dissolve in at least one solvent and get 
precipitated using a miscible non-solvent. This poses challenges of potential toxicity 
from solvent media and its complete removal from the final drug preparation [57].  
Wet ball milling technique uses a milling chamber to comminute a drug material that 
is dispersed in water and agitated along with surfactants or stabilisers. In this 
technique, mechanical shear and attrition is used due to collision of the drug 
particles with each other, milling media and walls of the milling chamber [58]. Small 
pearls, stainless steel, cross linked polystyrene, glass or ceramic beads of size 0.3 
mm or higher are used as milling media. However, the final size of the drug 
nanoparticles depends on other factors such as viscosity of the dispersion media, 
concentration of the surfactant, temperature conditions, duration of milling process 
and properties of drug dispersed [59]. 
The bottom up process offer smaller particle sizes than most top down approaches 
but its production scale is also much smaller. The fundamental of this process is 
precipitation of drug nanocrystals in two steps procedure: nucleation followed by 
crystal growth [60]. Hence it is important to control the nucleation step since if the 
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number of nuclei formed is higher, it will limit the growth of every nuclei. The use of 
ultrasound in combination to precipitation process results in cavitation effects which 
can speed up the nucleation process and minimize agglomeration [60, 61].  
Another bottom up process is called as evaporative precipitation in aqueous solution, 
where the drugs are dissolved in ethanol at 60°C. The solution is then added 
dropwise with constant stirring into water at 0°C. This temperature difference 
promotes supersaturation and nucleation which leads to a smaller size as compared 
to HPH technique. For example, the anticancer drug riccardin D was prepared as 
nanocrystals using evaporative precipitation and HPH technique with a size of 184 
nm and 815 nm respectively [51]. This study shows that a smaller particle size can be 
prepared using evaporative precipitation as a bottom up process which provides a 
higher control on particle size.  
Precipitation techniques of bottom up processes usually produces nanodrugs of 
lower crystallinity as various factors affect the polymorphic form of the drug 
nanoparticles, such as degree of supersaturation, type of solvent-antisolvent, etc. 
Solid state characterisation techniques such as XRD, NMR, DSC and FTIR can be 
used to study the crystallinity and other properties. However, the amorphous state of 
the nanoparticles is thermodynamically favourable during precipitation since it 
exhibits a metastable state with high energy that imparts quicker solubility of the 
drug. But, the property of the drug is also a significant factor to determine the 
resulting state of nanoparticles, as some drugs like Ibuprofen mostly precipitates in 
crystalline state, whereas Cefuroxime axetil precipitates as amorphous particles [62, 
63].  
The structural differences between the two (crystalline and amorphous) states of 
nanoparticles impart unique properties to the drugs which is exhibited either as 
advantages or disadvantages in terms of properties and specific applications. For 
instance, Table 2 critically studies both amorphous and crystalline drug nanoparticle 
along with their respective potential merits and demerits [46 - 48, 64 - 69].  
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Table 2. Comparison of amorphous and crystalline nanoparticles 
Types of Drug 
Nanoparticles 
Advantages Disadvantages 
Amorphous 
NPs 
Disorderedness improves 
thermodynamic driving force 
Wide size range (nm to µm) 
High water solubility Abrupt surface areas 
Enhanced Dissolution rate Low impurity of drug 
High oral absorption 
Physical and chemical instability in GI 
tract 
High saturation solubility (Ex- 
Chloramphenicol palmitate) 
High pharmacokinetic variability 
Ease of production Low suitability for intravenous routes 
Crystalline 
NPs 
Low pharmacokinetic variability in 
patients 
Lattice energy barrier for dissolution 
limits 
Narrow size range of crystals (< 1 µm) Need stabilisation by surfactants 
Physical and Chemical Stability from 
enzymatic degradation 
Aggregation due to high surface area 
and surface energy 
High Purity and drug loading (100%) Requires extensive crystallisation steps 
Suitable for intravenous administration Low oral absorption 
 
Nanosuspensions for drug delivery 
Nanosuspensions are powerful for drug delivery applications and several latest 
review articles have provided an in depth discussion on the various routes of 
administration. In brief, it is important to focus on key developments in this area by 
reviewing strategic articles and routes of administration. For instance, oral drug 
delivery is one of the most preferred routes of drug administration but is limited due 
to low oral absorption and bioavailability. Drug nanoparticles in suspension can 
tackle this problem by increasing the area of absorption under the curve as shown by 
naproxen nanoparticles with a 218% increase. Danazol – an inhibitor of 
gonadotropin when used in suspension showed an increased bioavailability of 82.3 
as opposed to conventional dispersion of 5.2% [6]. In addition, lyophilised 
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nanosuspensions offer faster dissolution rate with an increased permeability, as 
shown in case of oleanolic acid [70]. A schematic diagram shown in Figure 7 
highlights the enhanced permeability and retention (EPR) effect of drug 
nanocrystals, effective for tumour targeted drug delivery [71].  
 
Figure 7: EPR effect; (A) Normal vessel: the narrow gap junctions present in 
between endothelial cells allow only small molecules to penetrate, screening out 
colloidal sized particles. Notice the ordered structure of cells in the presence of 
functional lymphatic drainage. Lymph flow regularly filters out accumulated material. 
(B) Tumour microenvironment: The vascular endothelium in and around tumour is 
disjointed, irregular and leaky allowing effective penetration of nanocrystals. Absent 
or dysfunctional lymphatic vessels further delay clearance of these particles leading 
to their enhanced accumulation at tumour site (Reproduced with permission from ref 
[71]). 
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Nanosuspensions are also compatible for parenteral routes of drug administration 
like intravenous, interperitoneal and intra-articular. One of the key requirements for 
drug molecules administered through parenteral route is to highly soluble or have a 
particle size of less than 5 µm to prevent blockage of capillaries. It has been reported 
that nanosuspensions have increased the efficiency of parenterally administered 
drugs like paclitaxel [72], aphidicolin [73], clofazimine [74] and busulfan [75].  
Pulmonary drug delivery is dependent on the solubility of the drugs in pulmonary 
secretions. It is possible to nebulise the aqueous nanosuspensions using ultrasonic 
or mechanical nebulisers for delivery to lungs. This can lead to a uniform distribution 
of the drug nanoparticle in the aerosol droplet allowing for rapid dissolution and 
diffusion in the lungs. Furthermore, the adhesiveness of the drug to the mucosal 
membrane will be increased and therefore prolonging the drug’s residence time at 
the site of absorption. One such example is seen from budesonide drug that was 
nebulised successfully using an ultrasonic nebuliser [6]. 
Other key applications include use of nanosuspensions for ocular drug delivery as 
shown by dexamethasone study for anti-inflammation activity in rabbit [76], targeted 
drug delivery as shown by aphidicolin study against Leishmania-infected 
macrophages [73], mucoadhesion of drug for reducing infection as shown by 
mucoadhesive Buparvaquone [6] and topical drug delivery [8]. 
In vitro stability of drug nanocrystals 
Some of the areas of concern for in vitro stability are related to the pharmaceutical 
application of drug nanocrystals such as agglomeration, crystal growth and 
sedimentation. Drug nanocrystals can undergo amorphisation, especially upon 
application of nanosuspension methodologies such as top down and bottom up 
approaches [77]. Stabilisers are normally used to prevent the agglomeration of drug 
nanocrystals but it was found that drug-polymer interactions can substantially reduce 
the crystallinity. For instance, a study provided concrete evidence of Naproxen drug 
undergoing amorphisation due to the generation of amorphous layer on nanocrystals 
surface when subjected to media milling in the presence of hydroxypropyl 
methylcellulose [78].  
Cell culture assays are generally the standardised protocol for evaluating the 
performance of drug nanocrystals. However some of the key limitations of these 
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assays are linked to their working conditions and parameters. For instance, a 
fundamental limitation of these assays is due to its finite volume and closed system 
features. This can greatly affect the therapeutic efficacy and dissolution rate of the 
drug depending on the administered dose, especially if it is above the drug’s 
saturation solubility. This in turn affects the cytotoxicity based on the incubation time, 
since the low dissolution rate drugs naturally exhibit lower cytotoxicity effects [79]. A 
recent study has established these results by showing that longer incubation times 
such as 72 hours, for 240 nm Camptothecin’s drug nanocrystals showed similar 
cytotoxicity results as that to the solution [80].  
Furthermore, a recent study also established the fact that drug nanocrystals can 
aggregate within the cells to form rough edges with time. This can greatly affect the 
overall size and shape of the drug nanocrystals and therefore degrade the drug’s 
pharmacokinetics and its release. For instance, in the study, antiretroviral drug 
Ritonavir was loaded as large drug nanocrystals of about 300 to 900 nm into the 
macrophages. It was found that 24 hour post uptake, 68% of the drug nanocrystals 
were intact due to aggregation and acted as rough edged reservoirs to sustainably 
release the drug over a period of 2 weeks and longer [81]. As an extension to this 
work, it was also found that surfactant coating, shape and type of drug nanocrystals 
were influential parameters which affected its release, uptake and antiretroviral 
activity. It was found in the study that drug nanocrystals with irregular and round 
edges showed low cell uptake, while rod shaped drug nanocrystals showing regular 
and smooth edges showed a rapid uptake and release from macrophages [82].        
In vivo stability of drug nanocrystals 
A wide range of factors affect the stability and performance of drug nanocrystals in in 
vivo, such as the dissolution rate, half-life, charge, shape, particle distribution profile 
and toxicity effects. Both biological and physicochemical parameters affect the 
biodistribution and pharmacokinetics of the drug nanocrystals in in vivo. For 
instance, a study highlighted the effect of agglomeration on the cell’s uptake 
efficiency, showing that drug nanocrystals of size 50-100 nm were not internalised by 
the cells [83]. Furthermore, the un-dissolved drug nanocrystals injected intravenously 
remained in blood and interacted with plasma proteins that lead to surface 
opsonisation and formation of protein-drug agglomerates. This facilitates the 
recognition and clearance of the protein-drug agglomerates from the blood by the 
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tissue macrophages and circulating phagocytes that are directly in contact with blood 
[84]. 
Dissolution of the drug nanocrystals and its accumulation in liver and spleen are the 
key limitations which is inherent of the nanocrystals [85]. There are several studies 
which demonstrates the dissolution profile of low cytotoxic drug nanocrystals in in 
vivo models such as rats, dogs, rabbits, etc and also pinpoint their accumulation  in 
tissues, especially the macrophages of spleen and Kupffer cells of the liver [86]. 
Figure 8 presents a recent study showed the in vivo application of 450 nm Veirapine 
nanocrystals in mice [87]. The study indicated an EPR effect in the liver of mice for the 
drug nanocrystals as compared to drug in solution. However, the size of drug 
nanocrystals significantly affects their dissolution and accumulation profiles. For 
instance, a study showed the use of nanocrystals of Oridonin drug with two sizes 
ranges; 100 nm and 900 nm. It was found that when these drug nanocrystals were 
IV injected in rabbits, the 100 nm nanocrystals showed complete dissolution within 
10 minutes whereas the 900 nm nanocrystals underwent complete dissolution in 2 
hours [88].      
 
Figure 8: Particle-like behavior of NCs in vivo. (A) Gamma scintigrams depicting 
biodistribution of bare radiolabelled nevirapine 450-nm NCs and NCs surface-coated 
with albumin and dextran at 1 h and 24 h in rat compared to the drug in solution. 
(Reproduced with permission from reference [87]) 
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Benefits of nanosuspensions in drug delivery 
There are several benefits of nanosuspensions for use in drug delivery applications, 
such as [89 - 91]: 
• improves solubility of drugs insoluble in organic media and water, as 
alternative to lipid systems 
• helps to decrease the dosage requirements by increasing absorption and 
bioavailability of drugs 
• helps in formulations of high melting point and high log P value drugs 
• reduces systemic toxicity of drugs 
• increased physical stability of drugs 
• offers high resistance to oxidation and hydrolysis 
• offers passive targeting 
Conclusion  
To this date, various types of nanoparticles are employed in the field of 
nanomedicine, for drug delivery, imaging, diagnostics and several other applications. 
Even though a large number of studies are dedicated towards the carrier molecules 
such as organic and inorganic nanoparticles, it is important to understand the 
physiochemical properties of the effective drug itself for both in vivo and in vitro 
studies. There are several different processes that are used for synthesising the drug 
nanoparticles in both crystalline and amorphous forms, but these processes are 
broadly classified as top down and bottom up approaches. It is therefore important to 
choose the right methods of nanosizing the drug to control the degree of crystallinity 
and properties like particle size, morphology and surface areas.  
Nanosuspensions are an attractive solution for drug delivery, especially for oral and 
dermal routes of administration and are in turn favourable towards both amorphous 
and crystalline drug nanoparticles. It is highly anticipated that nanosuspension can 
dramatically improve the drug efficacy and bioavailability for all major drug classes, 
provided suitable solvents and stabilising agents are discovered. Therefore further 
studies should be directed towards finding a surfactant free route of drug delivery 
such as the food-derived or blood-derived proteins which poses no toxicity problems 
in vivo.  
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Future Perspective 
Targeted nanodrugs have already showed higher performance as compared to 
conventional drugs through almost all routes of administration. However the number 
of nanomedicines commercialising every year is far less than the total articles 
published. There seems to be a gap that is created between the laboratory tests and 
actual clinical trials due to the various differences that arise during scale up process 
and clinical trial stage. Therefore, adequate characterisation should be carried out for 
the synthesised drug nanoparticles and performance should be evaluated based on 
specific parameters such as surface area, surface charge and dispensability in 
nanosuspension. Foremost, crystallisation methods should be standardised for 
certain drug classes and appropriate control should be established on the aspect 
ratio of the drug nanocrystals for potential drug delivery both via passive and active 
targeting routes. 
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Executive summary 
 
Fabrication of drug nanoparticles in suspension 
• Drug particles in nanosuspension mitigate solubility and bioavailability issues 
of drugs. 
• Two main approaches for the synthesis of nanosuspension such as top-down 
and bottom up. 
• Crystalline and amorphous nanoparticle with variety of shapes, sizes and 
morphology can be designed  
• A range of characterisation techniques can be used for tuning the properties 
of drug nanoparticles  
 
Nanosuspensions in Drug Delivery 
• Poor solubility of drug molecules triggered the development of drug 
nanoparticulates for drug delivery  
• Nanosuspensions are highly desirable for oral route of drug administration 
• It is also compatible for parenteral routes of drug administration like 
intravenous, interperitoneal and intra-articular. 
• Nebulising of nanosuspensions aids the drugs to be used for pulmonary 
routes 
• Drug nanocrystals have higher EPR (enhanced permeability and retention) 
effect 
• In vitro studies of drug nanocrystals are limited by agglomeration, crystal 
growth and sedimentation 
• In vivo studies of drug nanocrystals face challenges due to bio-distribution 
and dissolution barriers along with accumulation tendencies in liver and 
spleen.  
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